Peroxisome proliferator-activated receptor-γ in the renal mesangium

被引:15
作者
Hsueh, WA [1 ]
Nicholas, SB [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA
关键词
D O I
10.1097/00041552-200203000-00010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that are expressed in a variety of tissues, including the liver (PPARalpha), adipose tissue, vascular smooth muscle, the heart, skeletal muscle, and the kidney (PPARgamma). PPARdelta is expressed ubiquitously. The receptors function as transcription factors to regulate the expression of genes involved in lipid metabolism, cell growth and migration as well as insulin-mediated skeletal muscle glucose uptake. Although the mechanisms by which all these actions occur have not been completely worked out, ligands to these receptors function to improve lipid metabolism, insulin sensitivity, endothelial dysfunction and urinary albumin excretion in patients with diabetes. Thus PPARs appear to have enormous implications for the management of cardiovascular disease. Curr Opin Nephrol Hypertens 11:191-195. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 55 条
[1]   Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation [J].
Asano, T ;
Wakisaka, M ;
Yoshinari, M ;
Iino, K ;
Sonoki, K ;
Iwase, M ;
Fujishima, M .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2000, 1497 (01) :148-154
[2]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883
[3]   CAP defines a second signalling pathway required for insulin-stimulated glucose transport [J].
Baumann, CA ;
Ribon, V ;
Kanzaki, M ;
Thurmond, DC ;
Mora, S ;
Shigematsu, S ;
Bickel, PE ;
Pessin, JE ;
Saltiel, AR .
NATURE, 2000, 407 (6801) :202-207
[4]   Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse [J].
Beales, PE ;
Liddi, R ;
Giorgini, AE ;
Signore, A ;
Procaccini, E ;
Batchelor, K ;
Pozzilli, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 357 (2-3) :221-225
[5]   Evidence that TGF-β should he a therapeutic target in diabetic nephropathy [J].
Border, WA ;
Noble, NA .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1390-1391
[6]   BLOOD-PRESSURE-LOWERING BY PIOGLITAZONE - EVIDENCE FOR A DIRECT VASCULAR EFFECT [J].
BUCHANAN, TA ;
MEEHAN, WP ;
JENG, YY ;
YANG, D ;
CHAN, TM ;
NADLER, JL ;
SCOTT, S ;
RUDE, RK ;
HSUEH, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :354-360
[7]   Retinoid X receptor expression in skeletal muscle of nondiabetic, obese and type 2 diabetic individuals [J].
Codner, E ;
Loviscach, M ;
Ciaraldi, TP ;
Rehman, N ;
Carter, L ;
Mudaliar, S ;
Henry, RR .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (07) :830-834
[8]   Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats [J].
Diep, QN ;
Schiffrin, EL .
HYPERTENSION, 2001, 38 (02) :249-254
[9]   Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase [J].
Diep, QN ;
Touyz, RM ;
Schiffrin, EL .
HYPERTENSION, 2000, 36 (05) :851-855
[10]   Chronic subclinical inflammation as part of the insulin resistance syndrome -: The Insulin Resistance Atherosclerosis Study (IRAS) [J].
Festa, A ;
D'Agostino, R ;
Howard, G ;
Mykkänen, L ;
Tracy, RP ;
Haffner, SM .
CIRCULATION, 2000, 102 (01) :42-47